{"product_id":"cardiovascular-proteomics-techniques-applications-for-clinical-and-laboratory-research-hardback-9781394211135","title":"Cardiovascular Proteomics Techniques; Applications for Clinical and Laboratory Research (Hardback) 9781394211135","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eCardiovascular Proteomics Techniques\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003eApplications for Clinical and Laboratory Research\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eCristina Banfi (Edited by), Banfi (Author), Dominic M. Desiderio (Series edited by), Joseph A. Loo (Series edited by), Igor A. Kaltashov (Series edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781394211135, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 6 January 2026\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e576 pages\u003cbr\u003e28 x 19 x 3.4 cm, 1.438 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\u003cb\u003eDefinitive reference on studying proteome biomarkers through cardiovascular disease pathophysiology and applied mass spectrometry\u003c\/b\u003e \u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eCardiovascular Proteomics Techniques \u003c\/i\u003eexplores the intersection of cardiovascular disease pathophysiology and applied mass spectrometry to study proteome biomarkers. Leading experts provide a comprehensive overview of the physiopathology of cardiovascular system diseases, along with insights into their etiology and pathogenesis through proteomics. The book features 18 chapters covering a range of topics, including mass spectrometry, proteomics, atherosclerosis, heart biology, cardiovascular diseases, experimental models, network analysis, international proteomic initiatives, clinical proteomics, and sex and gender proteomics. \u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eCardiovascular Proteomics Techniques \u003c\/i\u003ealso includes in depth discussions on: \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAntibody-based technologies for multiplexed protein detection and quantification, and their complementary role to mass spectrometry-based protein profiling.\u003c\/li\u003e\n\u003cli\u003eNew findings from proteomic analysis regarding the pathogenesis of atherosclerosis.\u003c\/li\u003e\n\u003cli\u003eEmerging insights into the pathobiology of acute coronary syndromes.\u003c\/li\u003e\n\u003cli\u003eNetwork medicine as a new paradigm for cardiovascular disease research and beyond, with potential applications in drug repurposing.\u003c\/li\u003e\n\u003cli\u003eRecent advances in cardiovascular plasma proteomics and previously unexplored cardiac diseases, such as Takotsubo syndrome.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eThis book is ideal for researchers in mass spectrometry, proteomics, life sciences, and cardiovascular studies, \u003ci\u003eCardiovascular Proteomics Techniques \u003c\/i\u003eaims to enhance our understanding of cardiovascular issues among clinicians and stimulate future developments in proteomics for the diagnosis and treatment of cardiovascular diseases.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eList of Contributors xvii\u003c\/p\u003e \u003cp\u003ePreface xxiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Basic Concepts in Mass Spectrometry 1\u003cbr\u003e \u003c\/b\u003e\u003ci\u003ePietro Traldi and Gianluca Bartolucci\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 1\u003c\/p\u003e \u003cp\u003e1.2 Mass and Energy 2\u003c\/p\u003e \u003cp\u003e1.3 Mass Spectrometry-Based Proteomic Analyses 4\u003c\/p\u003e \u003cp\u003e1.4 Mass Spectrometry in Quantitative Protein\/Peptide Analyses 23\u003c\/p\u003e \u003cp\u003e1.5 Posttranslational Modifications Investigated by Mass Spectrometry 27\u003c\/p\u003e \u003cp\u003e1.6 Outlook and Conclusion 28\u003c\/p\u003e \u003cp\u003eReferences 28\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Overview of Antibody-Based Technologies for Multiplexed Protein Detection and Quantification and Their Complementarity to Mass Spectrometry-Based Protein Profiling 31\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSonia Eligini, Erica Gianazza, and Alice Mallia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 31\u003c\/p\u003e \u003cp\u003e2.2 Clinical Potentials of Mass Spectrometry-Based Proteomics 31\u003c\/p\u003e \u003cp\u003e2.3 Mass Spectrometry-Based Proteomic Analysis Workflow: from Biomarker Discovery to Validation 32\u003c\/p\u003e \u003cp\u003e2.4 Proteomic Analysis of Biological Samples: from Sample Preparation to Proteome Characterization for the Identification of Disease or Drug Candidates 34\u003c\/p\u003e \u003cp\u003e2.5 Applications of the Emerging Mass Spectrometry-independent Targeted Proteomic Technologies in the Cardiovascular Field 42\u003c\/p\u003e \u003cp\u003e2.6 Conclusions 57\u003c\/p\u003e \u003cp\u003eReferences 58\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 General Features of the Cardiovascular System 65\u003cbr\u003e \u003c\/b\u003e\u003ci\u003ePaul A. Iaizzo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 65\u003c\/p\u003e \u003cp\u003e3.2 Components of the Cardiovascular System 65\u003c\/p\u003e \u003cp\u003e3.3 Summary 77\u003c\/p\u003e \u003cp\u003eReferences and Resources 77\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Albumin and Cardiovascular Diseases 79\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eCristina Banfi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 79\u003c\/p\u003e \u003cp\u003e4.1.1 Structure and Functions of Human Albumin 79\u003c\/p\u003e \u003cp\u003e4.2 Conclusion 98\u003c\/p\u003e \u003cp\u003eReferences 99\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Platelets: From Biomarker Discovery to Drug Target Identification by Proteomics 107\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eCristina Banfi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Platelet Biology 107\u003c\/p\u003e \u003cp\u003e5.2 Platelet Activation and Signaling 108\u003c\/p\u003e \u003cp\u003e5.3 Platelets in Diseases 112\u003c\/p\u003e \u003cp\u003e5.4 Role of Proteomics in Platelet Study 115\u003c\/p\u003e \u003cp\u003e5.5 Post-translational Modifications of Platelet Proteins 124\u003c\/p\u003e \u003cp\u003e5.6 Conclusions 130\u003c\/p\u003e \u003cp\u003eReferences 131\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 The Role of Proteomics in Extracellular Vesicles Research in Cardiovascular Disease 139\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMaísa García-Arguinzonis and Lina Badimon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 History of EVs 139\u003c\/p\u003e \u003cp\u003e6.2 Classification of EVs 140\u003c\/p\u003e \u003cp\u003e6.3 Biogenesis of EVs 140\u003c\/p\u003e \u003cp\u003e6.3.1 Exosomes 140\u003c\/p\u003e \u003cp\u003e6.3.2 Microvesicles 141\u003c\/p\u003e \u003cp\u003e6.3.3 Apoptotic Bodies 143\u003c\/p\u003e \u003cp\u003e6.4 Other Extracellular Particles 143\u003c\/p\u003e \u003cp\u003e6.5 Source of EVs in Cardiovascular Disease Studies 144\u003c\/p\u003e \u003cp\u003e6.6 EV Isolation from Cell Cultures 144\u003c\/p\u003e \u003cp\u003e6.7 Collection of EVs from Blood 144\u003c\/p\u003e \u003cp\u003e6.8 Urine-EVs Separation 146\u003c\/p\u003e \u003cp\u003e6.9 EVs from Solid Tissue 146\u003c\/p\u003e \u003cp\u003e6.10 Storage of EVs 146\u003c\/p\u003e \u003cp\u003e6.11 Isolation and Purification Methods 147\u003c\/p\u003e \u003cp\u003e6.12 EV Separation Methods 147\u003c\/p\u003e \u003cp\u003e6.13 Characterization of EVs 150\u003c\/p\u003e \u003cp\u003e6.14 Proteomics 151\u003c\/p\u003e \u003cp\u003e6.15 EVs in Cardiovascular Diseases 155\u003c\/p\u003e \u003cp\u003e6.16 EVs in Atherosclerosis 155\u003c\/p\u003e \u003cp\u003e6.17 EVs in Myocardial Infarction 157\u003c\/p\u003e \u003cp\u003e6.18 EVs in Angiogenesis 159\u003c\/p\u003e \u003cp\u003e6.19 EVs in Heart Failure 160\u003c\/p\u003e \u003cp\u003e6.20 Engineered EVs 161\u003c\/p\u003e \u003cp\u003e6.21 EV Databases 162\u003c\/p\u003e \u003cp\u003e6.22 Conclusion 163\u003c\/p\u003e \u003cp\u003eReferences 163\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Proteomics of Human Lipoproteins in Cardiovascular Diseases 177\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eCristina Banfi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 177\u003c\/p\u003e \u003cp\u003e7.2 Chylomicrons Biogenesis and Metabolism 178\u003c\/p\u003e \u003cp\u003e7.3 Very Low-Density Lipoprotein 183\u003c\/p\u003e \u003cp\u003e7.4 Low-Density Lipoprotein 189\u003c\/p\u003e \u003cp\u003e7.5 Lipoprotein(a) 193\u003c\/p\u003e \u003cp\u003e7.6 High-Density Lipoprotein 196\u003c\/p\u003e \u003cp\u003e7.7 Methodological Approaches for Isolating Lipoproteins 200\u003c\/p\u003e \u003cp\u003e7.8 Multiplexing Analysis of Apolipoproteins in the Human Blood 202\u003c\/p\u003e \u003cp\u003e7.9 Conclusions 203\u003c\/p\u003e \u003cp\u003eReferences 204\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Extracellular Matrix in Cardiovascular Pathophysiology: Proteomic Insights and Advancements to Mass Spectrometry-Based Characterization 215\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eRachel Cahalane, Mandy E. Turner, Elena Aikawa, and Cassandra L. Clift\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 An Introduction to the Extracellular Matrix 215\u003c\/p\u003e \u003cp\u003e8.2 Extracellular Matrix in Cardiovascular Pathobiology 219\u003c\/p\u003e \u003cp\u003e8.3 Proteomic Targeting of the ECM 233\u003c\/p\u003e \u003cp\u003e8.4 Conclusions and Future Directions 235\u003c\/p\u003e \u003cp\u003eReferences 236\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Pathogenesis of Atherosclerosis: What We are Learning from Proteomics 255\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDavid del Rio-Aledo, Estefanía Núñez, Emilio Camafeita, Isabel Cerro-Pardo, Rafael Barrero, Ana Martínez del Val, Consuelo Marín, Luis Miguel Blanco-Colio, Jesús Vázquez, and Jose L. Martin-Ventura\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 255\u003c\/p\u003e \u003cp\u003e9.2 Fundamentals of Proteomics in Atherosclerosis 255\u003c\/p\u003e \u003cp\u003e9.3 Mechanisms Involved in Atherosclerotic Plaque Development and Progression 260\u003c\/p\u003e \u003cp\u003e9.4 Proteomic Biomarkers in Atherosclerosis 268\u003c\/p\u003e \u003cp\u003e9.5 Future Perspectives and Challenges in Atherosclerosis Proteomics 270\u003c\/p\u003e \u003cp\u003e9.6 Concluding Remarks 273\u003c\/p\u003e \u003cp\u003eReferences 273\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Emerging Insights into the Pathobiology of Acute Coronary Syndromes 283\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGabriele Nieddu, Marilena Formato, and Antonio J. Lepedda\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 283\u003c\/p\u003e \u003cp\u003e10.2 Searching for Circulating Biomarkers of ACS by Applying MS-based Technologies 289\u003c\/p\u003e \u003cp\u003e10.3 Atherosclerotic Plaque Dissection through Proteomics 299\u003c\/p\u003e \u003cp\u003e10.4 Conclusions 302\u003c\/p\u003e \u003cp\u003eReferences 303\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Valvular Heart Disease, from Physiopathology to Biomarker Discovery 313\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSasha A. Singh and Elena Aikawa\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 313\u003c\/p\u003e \u003cp\u003e11.2 Physiopathology of Valvular Heart Disease, a Historical Perspective 314\u003c\/p\u003e \u003cp\u003eReferences 333\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Pathophysiology of Heart Failure 341\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGiorgia Panichella and Alberto Aimo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 341\u003c\/p\u003e \u003cp\u003e12.2 Hemodynamic and Structural Changes 342\u003c\/p\u003e \u003cp\u003e12.3 Neurohormonal Dysregulation 344\u003c\/p\u003e \u003cp\u003e12.4 Cellular and Molecular Mechanisms 351\u003c\/p\u003e \u003cp\u003e12.5 Comorbidities and Multisystem Involvement 354\u003c\/p\u003e \u003cp\u003e12.6 Right Ventricle in Heart Failure 355\u003c\/p\u003e \u003cp\u003e12.7 Genetic Contributions to Heart Failure 356\u003c\/p\u003e \u003cp\u003e12.8 Heart Failure as a Continuum Spectrum 357\u003c\/p\u003e \u003cp\u003e12.9 Heart Failure with Preserved Ejection Fraction 358\u003c\/p\u003e \u003cp\u003e12.10 The Contribution of Proteomics in Heart Failure 360\u003c\/p\u003e \u003cp\u003e12.11 Conclusions 362\u003c\/p\u003e \u003cp\u003eReferences 362\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Diseases of the Aorta, Recent Insights 371\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eRaghav Gupta, Ashley Dinh, Sarah J. Parker, and Elizabeth L. Chou\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 371\u003c\/p\u003e \u003cp\u003e13.2 Epidemiology of Aortic Aneurysm and Dissection 372\u003c\/p\u003e \u003cp\u003e13.3 Aortic Physiology 373\u003c\/p\u003e \u003cp\u003e13.4 Investigation of Aortic Aneurysms and Dissections 374\u003c\/p\u003e \u003cp\u003e13.5 Summary of Genes Linked to Aortic Aneurysm and Dissection 375\u003c\/p\u003e \u003cp\u003e13.6 The Omics of Ascending Thoracic Aortic Aneurysm and Dissection 378\u003c\/p\u003e \u003cp\u003e13.7 The Unique Value of Proteomics for Hereditary Aneurysm Research 379\u003c\/p\u003e \u003cp\u003e13.8 Application of Proteomics to Aortic Aneurysms and Dissections 380\u003c\/p\u003e \u003cp\u003e13.9 Beyond Bulk Proteomics for Mechanistic Discovery in Aortic Aneurysms and Dissections 381\u003c\/p\u003e \u003cp\u003e13.10 Conclusion 385\u003c\/p\u003e \u003cp\u003eReferences 385\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Unveiling Sex and Gender Differences in Cardiovascular Diseases 391\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDaniela Trabattoni, Giovanni Teruzzi, Giuseppe Calligaris, and Sebastiano Gili\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 391\u003c\/p\u003e \u003cp\u003e14.2 Sex-Related Differences in Clinical Presentation, Risk Factors, and Diagnostic Evaluation of CAD 391\u003c\/p\u003e \u003cp\u003e14.3 Primary Prevention 392\u003c\/p\u003e \u003cp\u003e14.4 Detection of Coronary Artery Disease 394\u003c\/p\u003e \u003cp\u003e14.4.9 Mechanical and Emotional Stressors 400\u003c\/p\u003e \u003cp\u003e14.5 Acute Coronary Syndromes in Obstructive Coronary Disease 407\u003c\/p\u003e \u003cp\u003e14.6 Gender Differences in PCI Outcomes 407\u003c\/p\u003e \u003cp\u003e14.7 The Role of Coronary Imaging in Imaging 409\u003c\/p\u003e \u003cp\u003e14.8 Psychological Issues in Gender Cardiovascular Medicine 413\u003c\/p\u003e \u003cp\u003e14.9 Pathophysiology Basis of Non-Atherosclerotic Coronary Disease in Women 416\u003c\/p\u003e \u003cp\u003e14.10 The Contribution of Proteomics in Unveiling Sex and Gender Differences 417\u003c\/p\u003e \u003cp\u003eReferences 419\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Trends in Mass Spectrometry Imaging for Cardiovascular Diseases 431\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJohs Dannesboe and Berta Cillero-Pastor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 431\u003c\/p\u003e \u003cp\u003e15.2 Definition and Basic Principles of Mass Spectrometry Imaging 431\u003c\/p\u003e \u003cp\u003e15.3 Brief History of Mass Spectrometry Imaging in Biomedical Research 432\u003c\/p\u003e \u003cp\u003e15.4 Importance of Mass Spectrometry Imaging in Cardiovascular Disease Research 433\u003c\/p\u003e \u003cp\u003e15.5 Basic Principles and Workflow 433\u003c\/p\u003e \u003cp\u003e15.6 Small Molecule and Lipid Imaging in Cardiovascular Research 440\u003c\/p\u003e \u003cp\u003e15.7 Challenges and Limitations 442\u003c\/p\u003e \u003cp\u003eReferences 444\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Network Medicine: A New Paradigm for Cardiovascular Disease Research and Beyond 449\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eNiv Vigder, Stuart J. Cordwell, and Joseph Loscalzo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction to Network Medicine 449\u003c\/p\u003e \u003cp\u003e16.2 Introduction to Network Science and Biological Networks 450\u003c\/p\u003e \u003cp\u003e16.3 Progress Toward Reference Organismal Interactomes 459\u003c\/p\u003e \u003cp\u003e16.4 Complex Diseases Manifest as Nodal and Edgetic Perturbations 464\u003c\/p\u003e \u003cp\u003e16.5 Expanding the Interactome to Incorporate Complex Biological Phenomena 466\u003c\/p\u003e \u003cp\u003e16.6 Context-Specific Interactomes Resolve Complex Biological Heterogeneity 468\u003c\/p\u003e \u003cp\u003e16.7 Network Approaches Reveal Novel Disease Genes and Gene Products 471\u003c\/p\u003e \u003cp\u003e16.8 (Re)defining Relationships Between Diseases Using Network Medicine 472\u003c\/p\u003e \u003cp\u003e16.9 Network Approaches to Disease Reappraisal and Patient Subgrouping 473\u003c\/p\u003e \u003cp\u003e16.10 Network Approaches to Disease Pharmacology 476\u003c\/p\u003e \u003cp\u003e16.11 Conclusions 478\u003c\/p\u003e \u003cp\u003eReferences 479\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Recent Advances in Cardiovascular Plasma Proteomics 487\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eNicolai B. Palstrøm, Amanda J. Campbell, and Hans C. Beck\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 487\u003c\/p\u003e \u003cp\u003e17.2 Clinical Plasma Proteomics 488\u003c\/p\u003e \u003cp\u003e17.3 The Proteomics Toolbox: Analytical Methods in Cardiovascular Clinical Plasma Proteomics 491\u003c\/p\u003e \u003cp\u003e17.4 Application of Plasma Proteomics in Cardiovascular Research 500\u003c\/p\u003e \u003cp\u003e17.5 Challenges Regarding the Translation of Proteomics into the Clinic 504\u003c\/p\u003e \u003cp\u003e17.6 Recent Advances within Cardiovascular Plasma Proteomics 507\u003c\/p\u003e \u003cp\u003e17.7 Outlook 509\u003c\/p\u003e \u003cp\u003eReferences 510\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Unexplored Cardiac Diseases: Takotsubo Syndrome 523\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eLiam S. Couch\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Introduction 523\u003c\/p\u003e \u003cp\u003e18.2 Clinical Presentation 523\u003c\/p\u003e \u003cp\u003e18.3 Multifactorial Pathophysiology of Takotsubo Syndrome 524\u003c\/p\u003e \u003cp\u003e18.4 The Role of Catecholamine Signaling 525\u003c\/p\u003e \u003cp\u003e18.5 Cardiomyocyte Calcium Handling 527\u003c\/p\u003e \u003cp\u003e18.6 Deranged Cardiomyocyte Metabolism 527\u003c\/p\u003e \u003cp\u003e18.7 Myocardial Inflammation and Edema 528\u003c\/p\u003e \u003cp\u003e18.8 Estrogen Withdrawal Post-menopause 529\u003c\/p\u003e \u003cp\u003e18.9 Altered Coronary Blood Flow 529\u003c\/p\u003e \u003cp\u003e18.10 Genomic Associations 531\u003c\/p\u003e \u003cp\u003e18.11 Brain Heart Interaction 531\u003c\/p\u003e \u003cp\u003e18.12 Scope for Future Utilization of Proteomics 532\u003c\/p\u003e \u003cp\u003eReferences 532\u003c\/p\u003e \u003cp\u003eIndex 541\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Chemistry [\u003ca title=\"See our other books on Chemistry\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Chemistry%20%5BPN%5D%22\"\u003ePN\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley","offers":[{"title":"Brand New","offer_id":52433206968600,"sku":"9781394211135","price":173.69,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9781394211135.jpg?v=1784851826","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/cardiovascular-proteomics-techniques-applications-for-clinical-and-laboratory-research-hardback-9781394211135","provider":"Freshly Printed Books","version":"1.0","type":"link"}